Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study by Schuler, Martin, Prof, Cho, Byoung Chul, MD, Sayehli, Cyrus Michael, MD, Navarro, Alejandro, MD, Soo, Ross A, MBBS, Richly, Heike, MD, Cassier, Philippe Alexandre, MD, Tai, David, MBBS, Penel, Nicolas, MD, Nogova, Lucia, MD, Park, Se Hoon, MD, Schostak, Martin, MD, Gajate, Pablo, MD, Cathomas, Richard, MD, Rajagopalan, Prabhu, PhD, Grevel, Joachim, PhD, Bender, Sebastian, PhD, Boix, Oliver, PhD, Nogai, Hendrik, MD, Ocker, Matthias, MD, Ellinghaus, Peter, PhD, Joerger, Markus, MD

Get full text

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC by Zhou, Qing, XX, Soo, Ross A., XX, Chang, Gee-Chen, XX, Chiu, Chao-Hua, XX, Hayashi, Hidetoshi, XX, Kim, Sang-We, XX, Teraoka, Shunsuke, XX, Goto, Yasushi, XX, Zhou, Jianying, XX, Ho-Fun Lee, Victor, XX, Kim, Dong-Wan, XX, Han, Baohui, XX, Chung Man Ho, James, XX, Lin, Chia-Chi, XX, Lu, Shun, XX, Polli, Anna, XX, Calella, Anna Maria, XX, Martini, Jean-François, XX, Wong, Chew Hooi, XX, Mok, Tony, XX, Kim, Hye Ryun, XX, Wu, Yi-Long, MD

Get full text

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study by Solomon, Benjamin J, Prof, Besse, Benjamin, Prof, Bauer, Todd M, MD, Felip, Enriqueta, MD, Soo, Ross A, MD, Camidge, D Ross, Prof, Chiari, Rita, MD, Bearz, Alessandra, MD, Lin, Chia-Chi, MD, Gadgeel, Shirish M, Prof, Riely, Gregory J, MD, Tan, Eng Huat, MBBS, Seto, Takashi, Prof, James, Leonard P, MD, Clancy, Jill S, BS, Abbattista, Antonello, BSc, Martini, Jean-François, PhD, Chen, Joseph, PharmD, Peltz, Gerson, MD, Thurm, Holger, MD, Ou, Sai-Hong Ignatius, Prof, Shaw, Alice T, Prof

Get full text